Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 6, 2014
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)Christos Vaklavas, Andres Forero
Current Treatment Options in Oncology|November 4, 2011
How do I treat "triple-negative" diseaseChristos Vaklavas, Andres Forero-Torres
Therapeutic Advances in Hematology|April 23, 2013
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaChristos Vaklavas, Andres Forero-Torres
Seminars in Oncology|January 8, 2004
History of antibody therapy for non-Hodgkin's lymphomaAndres Forero, Albert F Lobuglio
Current Oncology Reports|July 22, 2015
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin LymphomaAmitkumar Mehta, Andres Forero-Torres
Clinical Lymphoma & Myeloma|March 8, 2008
Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold WarAndres Forero-Torres, Mansoor N Saleh
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebraeRuby F Meredith, Sui Shen, Andres Forero, et al.
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
The Surgical Clinics of North America|July 15, 2018
Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerLakisha Moore-Smith, Andres Forero-Torres, Erica Stringer-Reasor
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 6, 2014
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)Christos Vaklavas, Andres Forero
Current Treatment Options in Oncology|November 4, 2011
How do I treat "triple-negative" diseaseChristos Vaklavas, Andres Forero-Torres
Therapeutic Advances in Hematology|April 23, 2013
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaChristos Vaklavas, Andres Forero-Torres
Seminars in Oncology|January 8, 2004
History of antibody therapy for non-Hodgkin's lymphomaAndres Forero, Albert F Lobuglio
Current Oncology Reports|July 22, 2015
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin LymphomaAmitkumar Mehta, Andres Forero-Torres
Clinical Lymphoma & Myeloma|March 8, 2008
Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold WarAndres Forero-Torres, Mansoor N Saleh
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebraeRuby F Meredith, Sui Shen, Andres Forero, et al.
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
The Surgical Clinics of North America|July 15, 2018
Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerLakisha Moore-Smith, Andres Forero-Torres, Erica Stringer-Reasor
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Pageof 18